Publications by authors named "C Bruedigam"
Biomimetic semi-synthetic hydrogels formed from a combination of star-shaped poly(ethylene glycol) (starPEG) and the glycosaminoglycan, heparin, allows for the three-dimensional (3D) culture of various cells and tissues. In this chapter, we describe methods for the use of starPEG-heparin hydrogels to cultivate primary and immortalized human acute myeloid leukemia (AML) cells. The resulting 3D culture models allow for the study of AML development and response to chemotherapeutic agents.
View Article and Find Full Text PDFArticle Synopsis
- Telomerase helps many cancers, like acute myeloid leukemia (AML), live longer and here we study a new drug called imetelstat that fights these cancers.
- We tested imetelstat using special lab-grown cancer samples from real patients and found it can reduce cancer cells, especially in certain genetic types of AML.
- By understanding how imetelstat works, we created a better treatment plan that combines it with another type of chemotherapy to help it work even better against AML.
Clinical studies revealed detrimental skeletal and vascular effects of the insulin sensitizer rosiglitazone. We have shown earlier that rosiglitazone accelerates osteoblast differentiation from human mesenchymal stem cells (hMSC) at the expense of increased oxidative stress and cell death. In calcifying human vascular cells, rosiglitazone stimulates pathological mineralization, an effect diminished by the antioxidant resveratrol.
View Article and Find Full Text PDFArticle Synopsis
- Human telomeres, made mostly of the 5'-TTAGGG-3' sequence, protect chromosome ends from damage and prevent loss of genetic material during cell division.
- As telomeres shorten and reach the Hayflick limit, cells can stop dividing or die, which is significant in both normal and cancerous cells.
- The enzyme telomerase helps maintain telomere length and is often overactive in cancer; this review focuses on therapies targeting telomerase, highlighting imetelstat, which shows promise in treating myeloid malignancies.
Article Synopsis
- Acute myeloid leukemia (AML) is a type of cancer in the blood that can be caused by different genetic changes.
- Scientists are studying how these genetic changes affect the body's immune system's ability to fight or ignore the cancer.
- They found that one specific gene, Nras, helps the immune system fight AML, but another gene, Myc, can make it harder for the immune system to do its job.